Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.10.0.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Revenues $ 444 $ 394
Operating expenses:    
Research and development (related party of $877 and $957), net of grant income of $44 and $131 3,986 4,117
General and administrative (related party of $942 and $775) 10,685 10,551
Total operating expenses 14,671 14,668
Operating loss (14,227) (14,274)
Other income (expense):    
Interest expense (related party of $1,915 and $1,928) (1,915) (1,929)
Interest income 15 39
Royalty income 19 25
Total other income (expense) (1,881) (1,865)
Consolidated net loss (16,108) (16,139)
Net loss attributable to noncontrolling interest 3 1,607
Net loss attributable to iBio, Inc. (16,105) (14,532)
Preferred stock dividends (260) (90)
Net loss available to iBio, Inc. (16,365) (14,622)
Comprehensive loss:    
Consolidated net loss (16,108) (16,139)
Other comprehensive loss - foreign currency translation adjustments (1) 0
Comprehensive loss $ (16,109) $ (16,139)
Loss per common share attributable to iBio, Inc. stockholders - basic and diluted $ (1.54) $ (1.64)
Weighted-average common shares outstanding - basic and diluted 10,631 8,911